Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.
The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.
Kanen Wealth Management LLC, its managing member David L. Kanen, and two affiliated funds (Philotimo Fund LP and Philotimo Focused Growth & Income Fund) filed an Amendment No. 1 to Schedule 13G reporting their collective ownership of 635,073 shares of AYTU BioPharma, Inc. (“AYTU”) common stock as of 15 May 2025.
The filing shows that the group now beneficially owns approximately 10.3 % of AYTU’s 6,170,246 outstanding shares (per AYTU’s 14 May 2025 Form 10-Q). Ownership is held passively under Rule 13d-1(c):
- Philotimo Fund LP: 425,500 shares (6.9 %)
- Philotimo Focused Growth & Income Fund: 209,573 shares (3.4 %)
- Kanen Wealth Management LLC & David L. Kanen: deemed beneficial owners of the full 635,073 shares (10.3 %) through control of the two funds
The signatories certify the securities were not acquired with the purpose of influencing control of the issuer. All voting and dispositive powers are reported as shared; none of the parties report sole power to vote or dispose of the shares. The principal business address for all reporting persons is 6810 Lyons Technology Circle, Suite 160, Coconut Creek, FL 33073.
The disclosure establishes Kanen Wealth Management and its affiliates as a newly recognized 10 % passive institutional holder of AYTU, a potentially supportive signal for other investors given the stake size and long-only filing status.
On June 20, 2025, Aytu BioPharma, Inc. (AYTU) executed Amendment No. 6 to its Loan and Security Agreement with Eclipse Business Capital. The amendment affects both the company’s term loan and revolving credit facility.
- Maturity extension: The $13.0 million Eclipse Term Loan and the Eclipse Revolving Loan now mature on June 12, 2029, giving AYTU an additional four-year runway.
- Incremental liquidity: A $1.5 million incremental advance was added to the revolving facility, priced at SOFR + 5.50%.
- Amortisation schedule: Repayment of the incremental advance begins August 1, 2025 at $125,000 per month until the advance is fully repaid.
- Borrowing-base flexibility: The amendment increases borrowing-base availability by permitting 25% concentration limits on certain independent pharmacy distributors.
- Regulatory disclosure: The transaction constitutes a direct financial obligation (Item 2.03). A press release dated June 23, 2025 (Exhibit 99.1) publicised the amendment; no earnings or operational updates were included.
The deal strengthens near-term liquidity and extends debt maturities, though at a relatively high floating rate and with scheduled principal reductions that will affect future cash flow.